X4 Pharmaceuticals (austria) Gmbh

Janssen Pharmaceuticals, Inc.

Arsanis Biosciences Gmbh

Cebina Gmbh

Valéria Szijárto

Eszter Nagy

Gábor Nagy

Jolanta Lukasiewicz

Irina Mirkina

Adriana Badarau

Luis Guachalla

Gerhild Zauner

Zoltán Magyarics

Robert Konrat

Zóltan Magyarics

Luis Gauchalla

Zehra Visram

Gäbor Nagy

Maximiliano Vasquez

The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR)strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.

MDRimmunogen

The invention refers to an isolated antibody that specifically binds to O25b antigen ofstrains comprising at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in FIG., and optionally further comprising an antibody light chain variable region (VL), which comprises any of the CDR4 to CDR6 sequences as listed in FIG., or functionally active CDR variants of any of the forgoing CDR 1-6 sequences.

specific antibodies

The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody. 

Antibodies targeting a galactan-based O-antigen of K. pneumoniae

A method of treating a subject in need of anti-coronavirus treatment by providing a prophylactic or therapeutic treatment which includes an antiviral effective amount of an Azelastine compound, where the antiviral effective amount is 0.1-500 &#x3bc;g per dose. An Azelastine compound can also be used as an antiviral substance in a medicinal product for treating a biological surface to prevent coronavirus infection and/or coronavirus spread, or as a viral disinfectant.

Antiviral treatment

A method of treating a subject in need of anti-Coronavirus treatment comprising prophylactic or therapeutic treatment, with an antiviral effective amount of an Azelastine compound, wherein the antiviral effective amount is 0.1-500 &#x3bc;g per dose; use of an Azelastine compound as an antiviral substance in a medicinal product for treating a biological surface to prevent from Coronavirus infection and/or Coronavirus spread, and use of an Azelastine compound as viral disinfectant.

MDRspecific antibody

[object Object]

Growing community of inventors

Vienna, Austria

Valéria Szijárto